Testosterone Pellets vs Cream vs Injection: The Real Tradeoffs for Women

why the delivery method actually matters

Testosterone prescribing for women is one of the more contested corners of women's hormonal medicine. The 2019 Global Consensus Position Statement on the use of testosterone therapy for women — endorsed by the Endocrine Society, ISSWSH, NAMS, and several international societies — concluded that the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women, with individualized dosing kept in the physiological range a healthy younger woman would have.^[1] Other indications (energy, body composition, mood) have supportive clinical experience but weaker consensus-statement support. For the full regulatory and evidence picture, see the female testosterone prescribing landscape.

Once a physician and patient have decided to pursue testosterone therapy, the next decision is delivery method. This matters more than most readers realize. The three primary methods — compounded cream, pellets, and injection — produce meaningfully different pharmacokinetic profiles, different dose-adjustability characteristics, and they fit different patient preferences and clinical situations.

This article is educational. It isn't prescribing guidance for any individual reader. Specific delivery method selection and dosing are determined by the prescribing physician based on your health history, goals, and how you respond. There are no FDA-approved testosterone products for women in the US. All three delivery methods discussed here are off-label prescribing — either compounded by 503A pharmacies or approved for male testosterone replacement and dosed down for women.

compounded testosterone cream

Compounded testosterone cream is the most common delivery method in US off-label female testosterone prescribing. It's prepared by 503A compounding pharmacies in patient-specific strengths, usually as a topical cream in a base designed for skin absorption.

How it's used. The cream is applied daily, typically to the inner thigh, inner forearm, or vulva depending on the clinical indication. Application site affects absorption, and different sites may be preferred for different clinical reasons — systemic effects vs local genital effects, in particular, lead to different application choices. Specific dose and application details are determined by the prescribing physician.

Pharmacokinetics. Cream keeps testosterone levels in the blood relatively steady when you apply it every day. Daily application produces a more level serum testosterone than periodic injection does.^[1] Absorption efficiency varies by site and individual skin characteristics, which is part of why prescribers usually titrate dose based on how you're feeling and follow-up labs rather than prescribing a single standard dose.

Dose adjustability. This is the strongest feature of the cream approach. The prescribing physician can adjust dose easily — prescribing a different strength or a different volume per application — and the adjustment takes effect relatively quickly (days to a couple of weeks for serum levels to reflect the new dose). Patients who develop unwanted side effects (acne, hair changes, voice changes) can have dose reduced or discontinued quickly.

Compliance. Daily application is a commitment. Some women find this easier than periodic injections or in-office procedures. Others find it a nuisance. Compliance matters because the serum profile depends on daily application. Skipping days makes blood levels dip, which weakens the effect.

Transfer risk. One consideration specific to topical: skin-to-skin contact at the application site can transfer measurable amounts of testosterone to another person. This is particularly important in households with young children, where ongoing exposure to transferred testosterone isn't something you want for kids. Prescribers usually counsel patients on how to manage this — washing hands after application, covering the application site, avoiding application at times when transfer risk is elevated.

FDA approval. There's no FDA-approved testosterone cream for women in the US. Compounded testosterone cream isn't an FDA-approved product. Its use in female testosterone prescribing is off-label use of a compounded preparation.

testosterone pellets

Testosterone pellets are small cylinders of crystalline testosterone that a physician inserts under the skin, typically in the upper hip area, through a minor in-office procedure. The pellets dissolve slowly over 3-4 months, releasing testosterone continuously into the bloodstream during that period.

How it's used. Insertion is an in-office procedure — local anesthetic, small incision, insertion of the pellets, closure with sterile strips or a small suture. The procedure takes 10-15 minutes. Patients return 3-4 months later for the next insertion when the previous pellets have dissolved.

Pharmacokinetics. Pellets follow a characteristic pattern: testosterone levels are highest in the weeks right after insertion (some women report a "peak" feeling early on), then gradually fall over the following months before the patient returns for re-insertion. Some patients notice a symptomatic "trough" feeling toward the end of the pellet cycle.

Dose adjustability — the catch. This is the weakness of the pellet approach. Once the pellets are in, they can't be removed. If the dose is wrong — too high, producing unwanted side effects — you have to wait for the pellets to dissolve. That can take weeks. The insertion procedure isn't reversible in the way discontinuing a cream is.

Provider-to-provider variation in initial pellet dose selection has been a subject of clinical debate. Some commercial pellet dosing schemes have been criticized in the medical literature for pushing testosterone above the normal female range, with critiques published in women's health endocrinology journals arguing that physiologic dosing (keeping testosterone within the range a healthy younger woman would have) is the safer target.^[1] This is a real clinical disagreement in the literature, and reasonable prescribers disagree on what pellet-based initial dosing should look like for women.

Compliance. Pellets are low-compliance-burden — no daily application, no weekly injection. For patients for whom compliance is a significant barrier, this is the main appeal. For patients who want more control over their own dosing, it's a constraint rather than a benefit.

FDA approval. Pellets used in female testosterone prescribing are either compounded by 503A pharmacies or, in some cases, approved male testosterone pellet products (Testopel) dosed-down for women. Neither pathway constitutes FDA approval for female use. Off-label prescribing in both directions.

injectable testosterone

Injectable testosterone — most commonly testosterone cypionate, the same form widely used in male testosterone replacement — is used in female testosterone prescribing only rarely. Worth understanding why, and the contexts where some practitioners do use it.

How it's used (when used). Subcutaneous or intramuscular injection at intervals from weekly to every two weeks, at substantially lower doses than male testosterone replacement. Specific dosing is determined by the prescribing physician. The doses used for women are a fraction of what's used for men.

Pharmacokinetics. Injection produces a characteristic peak-and-trough profile — higher levels in the days right after injection, declining over the following week or two. For men, this profile is manageable because the trough level is still in the target therapeutic range. For women, because the total doses are much smaller and the gap between "too little" and "too much" is narrower, the peaks and dips between shots can cause swings in how she feels that cream or pellets don't produce.

Why it's rare in female prescribing. Most US prescribers use cream for women because it gives better steady-state physiology, better dose adjustability, and fewer concerns about peak-level effects (voice changes, mood effects, other androgenic side effects associated with transient high serum levels). Pellets are the second most common approach. Injection in female prescribing exists in specific clinical contexts — sometimes with prescribers who are also doing male TRT and extending their prescribing to female patients, sometimes in specific niche practices.

FDA approval. Testosterone cypionate is FDA-approved for male hypogonadism. Its use in female testosterone prescribing is off-label use of an FDA-approved male product.

head-to-head

The tradeoffs are clear. Cream offers dose control at the cost of daily compliance. Pellets offer convenience at the cost of dose control. Injection has neither advantage and is used for specific reasons in specific practices.

what prescribing physicians actually consider

The selection between delivery methods isn't formulaic. It's a clinical judgment informed by patient factors. What the clinical literature and practice patterns suggest prescribers typically weigh:

Compliance profile. A patient who reliably takes a daily medication can do cream. A patient who has struggled with daily medication adherence may do better with pellets. Honest compliance assessment matters more than aspirational commitment.

Clinical indication. For genital-specific concerns (arousal response, genital tissue health), topical cream applied to the vulva has an anatomical logic that systemic-only delivery doesn't. For systemic indications (libido, mood, energy, body composition), any of the three delivery routes can produce systemic effects.

Risk tolerance for over-delivery. Cream allows quick adjustment down if side effects emerge. Pellets don't. Risk-averse patients and risk-averse prescribers tend toward cream.

Household composition. Transfer risk from topical application matters most in households with young children. For those patients, pellets (no transfer risk) may be preferred even at the cost of dose control.

History of response. A patient previously well-managed on cream is usually continued on cream. A patient with inconsistent results on cream may be a candidate for pellets or a different mechanism.

Cost and insurance. Compounded products are typically not insurance-covered. Out-of-pocket costs vary; pellets often have a higher per-visit cost but, amortized to monthly, may be comparable to daily cream depending on the product and pharmacy.

the honest bottom line

For most midlife women beginning testosterone therapy under off-label prescribing, compounded cream is the appropriate first-line choice. It gives the best balance of dose control, steady-state physiology, and reversibility. The daily application is a real compliance burden for some patients, but for those who can sustain it, the clinical control is worth the effort.

Pellets are a legitimate second option, especially for patients for whom daily application isn't sustainable. The tradeoff is loss of dose control — patients need to understand that once the pellets are in, the dose is fixed for several months and can't be reduced if unwanted effects emerge. Prescriber selection matters particularly here, because provider-to-provider variation in initial pellet dose has been a source of clinical criticism when doses run high.

Injection is rare in female prescribing and should be approached with specific reasons. The peak-trough pharmacokinetic profile is less well-suited to women's narrower therapeutic window than to men's wider one, and the other delivery methods typically serve women better.

The choice between delivery methods is a clinical decision made by the prescribing physician in conversation with the patient, based on the full clinical picture. What this article can do is give you the vocabulary and the tradeoffs so you can have an informed conversation with a qualified prescriber. For context on what the overall female testosterone prescribing landscape looks like, see the female testosterone prescribing landscape.